Imipenem/Cilastatin Aptapharma (Cilastatin, Imipenem)

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, causing cell lysis. Cilastatin is co‑administered to block renal dehydropeptidase I, an enzyme that would otherwise degrade imipenem in the kidneys, thereby preserving its antibacterial activity and prolonging its plasma half‑life.

The dosing regimen for Imipenem/Cilastatin is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Healthcare providers calculate the appropriate dose and infusion schedule for each individual patient.

The safety of Imipenem/Cilastatin in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Imipenem/Cilastatin offers a broad spectrum of activity against many Gram‑positive, Gram‑negative, and anaerobic bacteria, similar to other carbapenems such as meropenem or ertapenem. Its unique combination with cilastatin protects the drug from renal degradation, allowing higher plasma concentrations, but the choice between agents depends on local resistance patterns, pharmacokinetic considerations, and clinician preference.

Imipenem/Cilastatin injectable solution should be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect from light, and avoid freezing or shaking the solution. Once removed from refrigeration, it may be used within the time frame specified in the product labeling.

The medication is given by intravenous infusion, typically over 30 minutes to one hour, depending on the prescribed dose and clinical protocol. Administration should be performed by qualified healthcare personnel in a setting equipped for IV therapy, with appropriate monitoring for infusion‑related reactions.

Serious adverse events include anaphylactic reactions, seizures (especially in patients with renal impairment or high doses), Clostridioides difficile‑associated colitis, and rare severe skin reactions such as Stevens‑Johnson syndrome. Prompt recognition and medical intervention are essential if any of these events occur.

Patients with a known hypersensitivity to imipenem, cilastatin, or any other carbapenem or β‑lactam antibiotics should not receive this product. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those taking medications that may interact significantly, such as valproic acid.